5.95

11.33% -0.76

After Hours: 6.05 0.10 +1.68%

Verve Therapeutics Inc (VERV)

Overview News Price History Option Chain Financials Why VERV Down? Discussions Forecast

Verve Therapeutics Inc stock is traded at $5.95, with a volume of 1.87M. It is down -11.33% in the last 24 hours and down -25.44% over the past month. Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Previous Close:

$6.71

Open:

$6.6

24h Volume:

1.87M

Relative Volume:

1.22

Market Cap:

$528.33M

Revenue:

$20.65M

Net Income/Loss:

$-192.65M

P/E Ratio:

-2.2973

EPS:

-2.59

Net Cash Flow:

$-134.39M

1W Performance:

-3.57%

1M Performance:

-25.44%

6M Performance:

+6.06%

1Y Performance:

-60.23%

1-Day Range:

$5.64

$6.73

1-Week Range:

$5.64

$6.81

52-Week Range:

$4.305

$15.55

Verve Therapeutics Inc Stock (VERV) Company Profile

Name

Verve Therapeutics Inc

Sector

Healthcare (1173)

Industry

Biotechnology (680)

Phone

(978) 501-3026

Address

201 BROOKLINE AVENUE, BOSTON

Employee

274

Twitter

Next Earnings Date

Latest SEC Filings

VERV's Discussions on Twitter

Compare VERV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VERV Verve Therapeutics Inc	5.95	528.33M	20.65M	-192.65M	-134.39M	-2.59
VRTX Vertex Pharmaceuticals Inc	500.01	128.40B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	744.83	81.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	571.00	34.69B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	233.07	30.17B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	242.66	26.02B	3.32B	-860.46M	-1.04B	-8.32

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-24	Initiated	H.C. Wainwright	Buy
Apr-13-23	Initiated	Canaccord Genuity	Buy
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral
Dec-15-22	Initiated	Goldman	Sell
Oct-06-22	Initiated	Credit Suisse	Neutral
Aug-25-22	Upgrade	Stifel	Hold → Buy
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Sep-24-21	Initiated	Stifel	Hold
Jul-12-21	Initiated	Guggenheim	Buy
Jul-12-21	Initiated	JP Morgan	Neutral
Jul-12-21	Initiated	Jefferies	Buy
Jul-12-21	Initiated	William Blair	Outperform

View All

Verve Therapeutics Inc Stock (VERV) Latest News

Mar 08, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World

Mar 08, 2025

Mar 07, 2025

IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Mar 07, 2025

Mar 06, 2025

(VERV) Technical Data - Stock Traders Daily

Mar 06, 2025

Mar 05, 2025

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World

Mar 05, 2025

Mar 04, 2025

Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks

Mar 04, 2025

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 04, 2025

Mar 03, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Mar 03, 2025

How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan

Mar 03, 2025

Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire

Mar 03, 2025

Analysts Set Expectations for VERV Q1 Earnings - Defense World

Mar 03, 2025

Mar 02, 2025

Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire

Mar 02, 2025

HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World

Mar 02, 2025

Mar 01, 2025

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire

Mar 01, 2025

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 01, 2025

Feb 28, 2025

H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada

Feb 28, 2025

Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks

Feb 28, 2025

Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights

Feb 28, 2025

Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha

Feb 28, 2025

Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks

Feb 28, 2025

Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks

Feb 28, 2025

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Feb 28, 2025

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Feb 28, 2025

Feb 27, 2025

Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Feb 27, 2025

Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle

Feb 27, 2025

Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada

Feb 27, 2025